BIDMC Mass Spectrometry Core Enables Discovery of TRIDENT, a New Driver of Drug Resistance in Lung Cancer

A recent PNAS publication from Dr. Frank Slack’s group uncovers TRIDENT, an EGFR-induced long non-coding RNA that plays a key role in tumor growth and chemoresistance in non–small cell lung cancer (NSCLC). The team shows that TRIDENT activates TRIM28-mediated DNA damage repair, allowing cancer cells to better withstand chemotherapy. Loss of TRIDENT leads to accumulated DNA damage, reduced proliferation, and increased sensitivity to drugs such as cisplatin and doxorubicin.

This mechanistic breakthrough was enabled by ChIRP-MS analysis performed using mass spectrometry at the BIDMC Mass Spectrometry Core, part of the BIDMC Omics Cores Network, which identified TRIM28 as a key TRIDENT-binding protein and helped illuminate how TRIDENT regulates DNA damage repair through TRIM28 phosphorylation.

Interested in mapping protein interactions or performing multi-omics analysis?

The BIDMC Mass Spectrometry Core offers advanced proteomics, metabolomics, phosphoproteomics, and isotope-tracing services to accelerate mechanistic discovery and pathway analysis.

• Read the full study
• Explore services offered by the Mass Spectrometry Core
• Explore other services offered by BIDMC Omics Cores